Our paper in @nature.com is finally published: a prospective trial of a personalized Neoantigen Vaccine in Kidney Cancer

www.nature.com/articles/s41...

This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab

www.nature.com/articles/s41...

Mortality Risk for Patients with Biopsy Gleason Grade Group 1 Prostate Cancer Approximately 8% of patients with a prostate biopsy result of Gleason grade group (GGG) 1 have occult high-risk prostate cancer. Maintaining the “cancer” classification for GGG 1 for cases with >50% p...

Another argument against removing “cancer” label for Pattern 3 easily prostate cancer refuted by replacing “pattern 3” with “benign”: men with pattern 3 / biopsy and PSA > 20 are at increased risk of mortality therefore call pattern 3 / benign “cancer” euoncology.europeanurology.com/article/S258...

Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm
acsjournals.onlinelibrary.wiley.com/doi/epdf/10....

Patient-centered pathology reports improved patients' understanding of prostate biopsy results and their ability to accurately assess their cancer diagnosis and risk level, compared to standard pathology reports.

ja.ma/4a3c38z

Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020 This model-based study using population-level cancer mortality data evaluates the association of prevention, screening, and treatment interventions with cumulative number of cancer deaths averted from...

Estimated 6 Million deaths from breast, cervical, colorectal, lung, and prostate cancers were averted in the US from 1975 to 2020 due to Prevention, Screening, and Treatment Advances @jama.com

jamanetwork.com/journals/jam...

Just out in @bmj.com, our "Uncertainties in Practice" article on #LATP vs #TRUS

We highlight evidence so far, discordance between recommendations (@UroWeb.bsky.social vs @NIHR.bsky.social vs #AUA) & need for nuance (!)

Not long now until #TranslateTrial...

bmj.com/content/387/bm…👈

While I totally agree on the need for BCR risk stratification, i do not know if PSADT will remain that important in the new era of PSMA imaging and MDT. EMBARK isnt a risk stratification, this cohort was choosen because no one doubts they need therapy immediately.

ascopubs.org/doi/10.1200/...

Patient Selection: What Tumors Should Be Treated Based on Grade, Size, Location, Genetics and Risk Category? Careful patient selection is essential for successful focal therapy (FT). In this section, we discuss the influence of tumor properties, its location, and the patient on optimal treatment planning. Fi...

💥 Just published💥
Wondering how #PSMA imaging and #genetics will influence focal therapy for #prostatecancer in the future? This book chapter discusses how modern patient selection for #focal therapy can improve cancer control outcomes.

Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR!

www.nature.com/articles/s41...

Maybe it is because in PEACE-1, pts on ADT alone had abi at PSA progression, and RT delayed PSA progression. Any benefit from RT could have been lost by harm from delayed abi

PEACE-1: rPFS for low volume mHSPC

PEACE-1 trial of prostate radiotherapy in mHSPC. Improvement in rPFS when used in addition to ADT and abiraterone. Medsky. Oncsky.

Industry Announcement: CAPItello281 Phase III Source AstraZeneca

Capivasertib combined with/ADT improved rPFS in PTEN-deficient met hormone-sensitive #ProstateCancer Vs abiraterone & ADT w/placebo
OS data immature, early indications suggest potential OS benefit

www.astrazeneca.com/media-centre...

🚨🚨Prostate and UREthra on MRI (PURE-MRI):
Try to contour (outline) the prostate and urethra on MRI for 1 patient
After everyone is done, we will enable the “answer key”
And you help us learn how to help doctors and AI do better
Sign up here: redcap.link/PURE-MRI
🙏🏼

Mechanisms of resistance to PARP inhibitors in advanced prostate cancer with BRCA2/PALB2 alterations: Reversion mutations emerge within 16 weeks. These associate with disease progression and survival.
#Cancer #Oncology @oncoalert.bsky.social @apccc.bsky.social
www.sciencedirect.com/science/arti...

Matching patients to clinical trials with large language models - Nature Communications Patient recruitment is challenging for clinical trials. Here, the authors introduce TrialGPT, an end-to-end framework for zero-shot patient-to-trial matching with large language models.

'TrialGPT' A new chatGPT for clinical trials @natureportfolio.bsky.social:

- 3 steps: TrialGPT-Retrieval, TrialGPT-Matching, TrialGPT-Ranking
- Retrieval identified 90% suitable trials
- 42% time-saving in matching a patient to a trial

Like, wow
#MedSky #OncSky #LCSM
www.nature.com/articles/s41...

Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study An AI system was superior to radiologists using PI-RADS (2.1), on average, at detecting clinically significant prostate cancer and comparable to the standard of care. Such a system shows the potential...

What’s your single favorite #prostatecancer paper of the year so far?

I’ll lead with PI-CAI: big leap forward for prostate MRI through a highly collaborative AI effort. And the best part is it’s all free and *open-source*! ⭐️

www.thelancet.com/journals/lan...